Angiology: Open Access
Open Access

Tomohiro Sakamoto

Biography

Division of Cardiology, Cardiovascular Center, Saiseikai Kumamoto Hospital....RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers (NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.

Relevant Topics